The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of lenvatinib by starting dose (8 mg or 12 mg) based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.
 
Takuji Okusaka
Honoraria - AstraZeneca Japan; Bayer Yakuhin; Bristol-Myers Squibb; Celgene; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; EA Pharma; Eisai; Fujifilm; Lilly; Nippon Chemiphar; Nobelpharma; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Daiichi Sankyo; Dainippon Sumitomo Pharma; Taiho Pharmaceutical; Zeria Pharmaceutical
Research Funding - AstraZeneca Japan; Bayer Yakuhin; Dainippon Sumitomo Pharma; Eisai; Kowa; Kyowa Hakko Kirin; Lilly; Merck Serono; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Yakult Honsha
 
Kenji Ikeda
Honoraria - Dainippon Sumitomo Pharma; Eisai
 
Masatoshi Kudo
Honoraria - Abbvie; Bayer; Bristol-Myers Squibb Japan; EA Pharma; Eisai; Gilead Sciences; Merck Serono; Merck Serono; MSD; Novartis; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; MSD
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
Richard S. Finn
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Genentech/Roche; Lilly; Merck; Novartis; Pfizer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
 
Shukui Qin
No Relationships to Disclose
 
Kwang-Hyub Han
Research Funding - Bayer; Dainippon Sumitomo Pharma; Eisai; Kowa
 
Ann-Lii Cheng
Honoraria - AstraZeneca; Bayer Yakuhin; Eisai; Genentech/Roche
Consulting or Advisory Role - AstraZeneca; Bayer Schering Pharma; Bristol-Myers Squibb; CSR Pharma; Eisai; Genentech/Roche; MSD; Novartis; Ono Pharmaceutical
 
Fabio Piscaglia
Honoraria - Bayer; Bracco Diagnostics; Eisai
Research Funding - Bayer
 
Masahiro Kobayashi
Honoraria - Abbvie; EA Pharma; Eisai; Gilead Sciences; Nippon Kayaku; Sumitomo Dainippon
 
Max W. Sung
Consulting or Advisory Role - Bayer; Eisai
 
Minshan Chen
No Relationships to Disclose
 
Lucjan Wyrwicz
No Relationships to Disclose
 
Jung-Hwan Yoon
Research Funding - AstraZeneca; Bayer
 
Zhenggang Ren
No Relationships to Disclose
 
Daniel E. Stepan
Employment - Eisai
 
Corina E. Dutcus
Employment - Eisai
Leadership - Eisai
 
Toshiyuki Tamai
Employment - Eisai
 
Min Ren
Employment - Eisai
Leadership - Eisai
 
Seiichi Hayato
Employment - Eisai
 
Hiromitsu Kumada
Honoraria - Abbvie; Ajinomoto; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Janssen; Kowa; Mitsubishi Tanabe Pharma; MSD; Otsuka; Sumitomo Dainippon; Toray Industries; Toray Industries